Answers are grounded in this paper and cite their sources.
Oral disorders: Oral biofilms harbor pathogenic bacteria, viruses, and mycobionts that contribute to major oral diseases, including dental caries, periodontitis, and oral cancers. Increasing evidence, particularly in oral oncology, indicates that disease outcomes are shaped not only by pathogenic members but also by commensal microbes that can curb or outcompete deleterious species. Accordingly, alongside antimicrobial strategies aimed at disrupting pathogenic biofilms, approaches that selectively enhance beneficial microbial populations may represent effective complementary interventions for the management of biofilm-associated oral diseases (Di Pierro et al., Lv et al., Lasica et al., Perez-Losada et al., Popowski et al., Glavina et al, 2026., Chiscuzzu et al., 2025., Foroughi et al., 2025., Govindarajan et al., 2025., Priya et al., 2025., Baker et al., 2024).Lasica et al. provide a comprehensive review of the inflammatory etiology of periodontitis that results in progressive damage to gingival tissues, periodontal ligaments, cementum, and alveolar bone, ultimately leading to tooth loosening and loss. Beyond oral pathology, periodontitis is associated with systemic, cerebral, and reproductive disorders. Conventional management approaches, including oral hygiene improvement, mechanical plaque removal, and antimicrobial therapy, remain effective in reducing pathogen burden; however, rising antibiotic resistance [microbes within biofilms may be up to 1,000 times more resistant to antibiotics than their free counterparts] and the failure of standard techniques to fully eliminate the deleterious microbes substantially limit their long-term efficacy. Alternative antimicrobial strategies, such as bacteriophage therapy and bacteriotherapy, have therefore gained attention. Bacteriophages can selectively inhibit oral pathogens, but their clinical application remains constrained by limited phage availability. Predatory Gram-negative bacteria, including Bdellovibrio and related organisms (Salah et al., 2025), have demonstrated the ability to reduce key periodontal pathogens (Aggregatibacter actinomycetemcomitans and F. nucleatum) in biofilm models, promote beneficial microbial communities, and exhibit protective effects in pre-clinical animal models. Further research is required to elucidate their mechanisms of action and clinical potential.Oral infections extend beyond epithelial and dental surfaces and represent a major challenge in oral and maxillofacial surgery. Popowski et al. and Choi & Hong (2026) report that pathogencontaining biofilms associated with local tissues and prosthetic materials, which are often highly susceptible to bacterial colonization, contribute to adverse clinical outcomes, including postoperative infections, delayed healing, impaired prosthetic integration, and surgical failure. Autogenous bone remains the preferred grafting material, but its limited availability has increased reliance on xenogeneic and alloplastic substitutes, which are susceptible to microbial colonization and require careful control. Emerging antimicrobial biomaterials, including silverand strontium-doped hydroxyapatite, copper-and zinc-enriched bioglasses, and chitosan-based calcium phosphate scaffolds, show promise by coupling osteogenic potential with biofilm suppression. Nevertheless, strict infection control measures, such as preoperative antiseptic rinses, single-dose antibiotic prophylaxis, and meticulous surgical techniques, remain critical for minimizing microbial risk and ensuring clinical success.Oral biofilm pathogens, including P. gingivalis and F. nucleatum, are increasingly linked to the risk, incidence, and severity of multiple systemic conditions. These include respiratory diseases, type 2 diabetes mellitus, cardiovascular disease, rheumatoid arthritis, bone disorders, hepatic and metabolic dysfunctions, inflammatory bowel diseases, and both intestinal and systemic cancers. These disorders may arise directly via microbial translocation to distal tissues, or indirectly through the systemic dissemination of virulence factors and microbial metabolites. In addition, oral microbes or their metabolic products may reshape the gastrointestinal microbiome and metabolome (Lasica et al., Perez-Losada et al., Glavina et al., 2026., Bruno et al., 2025., Harrandah, 2025., Hu et al., 2025., Kumar and Tyagi, 2025., Kurtzmann et al., 2025a., Kurtzmann et al., 2025b., Nayak et al., 2025., Zhang & Zhang., 2025., Baker et al., 2024).Pérez-Losada et al. demonstrated that oral dysbiosis is associated with allergic rhinitis (AR) and its progression to asthma (ARAS). Patients with AR or ARAS showed increased abundance of Fusobacteriota and Pseudomonadota, along with reduced abundance of Actinobacteriota and Bacillota. At the genus level, Fusobacterium, Gemella, Haemophilus, Leptotrichia, Neisseria, Porphyromonas, and Prevotella were enriched, whereas Actinomyces, Streptococcus, and Veillonella were depleted. Functional analyses indicated upregulation of metabolic pathways linked to allergic sensitization, airway inflammation, and immune responses, supporting oral dysbiosis as a contributory factor in AR onset and progression to ARAS.Akkermansia muciniphila, traditionally recognized as an intestinal commensal, is also detectable in saliva and has been shown to suppress oral inflammation and inhibit periodontal pathogens, including P. gingivalis and F. nucleatum (Anderson et al., 2024). Recent in vivo research by Zhang et al. demonstrates that patients with severe periodontitis exhibit marked gut dysbiosis, characterized by elevated pathogenic taxa and reduced levels of beneficial microbes, such as A. muciniphila. The abundance of A. muciniphila was partially restored in patients following conventional periodontal therapy. In a murine model of periodontitis, which displayed inflammation and compromised intestinal barrier integrity, fecal levels of A. muciniphila were also greatly reduced. Transplantation of the fecal microbiota from periodontitis patients to these mice perpetuated both alveolar bone loss and intestinal pathology, whereas transplantation from healthy donors substantially ameliorated deleterious effects. Together, these findings underscore the bidirectional oral-gut axis, whereby gut microbial composition and metabolites influence the severity of periodontitis, while oral inflammatory states reciprocally modulate gut microbiome structure and intestinal health.Brain dysfunction: Growing evidence links oral biofilm-associated pathogens with an increased risk and severity of neurological and neuropsychiatric conditions, including Alzheimer's disease, Parkinson's disease, autism spectrum disorder, anxiety, depression, and age-related cognitive decline. Although the underlying mechanisms remain poorly defined, these effects may involve the translocation of oral microbes or their metabolites via an oral-brain axis, or indirect signaling through the oral-gut-brain axis (Lasica et al., Glavina et al., 2026., Adil et al., 2025., Borrego Ruiz & Borrego., 2025., Clasen et al., 2025., Kong et al., 2025., Kumar & Tyagi., 2025., Miranda et al., 2025., Rozenblum et al., 2025., Baker et al., 2024).Biofilm modulation: Multiple agents and techniques are used to disrupt oral biofilms and suppress periodontal pathogens. However, while generally effective, they are often non-selective, eliminating both commensal and pathogenic microbes. (Fydrych et al., 2025., Narwal et al., 2025). Studies to find more discriminating treatment procedures are of high importance (Ciren et al., 2026., Wu et al., 2026). Bueno-Silva et al. evaluated an oral gel containing Aloe vera, propolis extract, green tea, cranberry, and calendula on a multispecies oral biofilm model comprising 33 bacterial species. When applied as a toothpaste alternative (eight 1-min applications at 12-h intervals), the formulation significantly reduced total bacterial counts, although its efficacy was lower than that of chlorhexidine + cetylpyridinium chloride or stannous-fluoride toothpastes. Notably, a single 12-h treatment produced marked effects, reducing biofilm metabolic activity by 45% and total bacterial load by 59% across 24 species. Substantial reductions were observed in F. nucleatum polymorphum, Prevotella intermedia, and P. gingivalis, with a particularly pronounced decrease in T. forsythia, a key pathogen in periodontitis and peri-implantitis. Siddiqui et al. studied a new herbal mouthwash (Azadirachta indica, Calendula officinalis, Echinacea purpurea, and Plantago major) in vitro and ex vivo. The formulation selectively inhibited key periodontal pathogens (including F. nucleatum and P. gingivalis) while sparing commensals (e.g., Streptococcus oralis, Streptococcus gordonii, and Veillonella parvula). In a mixed-species biofilm model, pathogen burden fell markedly without disrupting overall biofilm integrity. In studies with pure compounds, Dong et al. evaluated whether the human cathelicidin-derived antimicrobial peptide LL-37 and polymyxin B could dampen LPS-driven inflammation in saliva and subgingival biofilm samples from healthy, gingivitis, and periodontitis patients. Pretreatment with either peptide reduced THP-1 monocyte inflammatory responses, attenuating NF-κB/IRF signaling and lowering IL-1β, IL-6, IL-8, and TNF-α, with minimal effects on anti-inflammatory mediators (TGF-β, IL-10). Taude et al. assessed S-0636, a small-molecule inhibitor of glutaminyl cyclase (present in P. gingivalis, T. forsythia, and P. intermedia). When P. gingivalis was used as a test model, S-0636 strongly inhibited the enzyme and reduced bacterial virulence by >70% at ≤62.5 μM. By contrast, it had no detectable effects on oral commensals at 0.25 mM. Furthermore, Eick et al. showed that S-0636 suppressed a 12-species oral biofilm model: at ≥125 μM, it reduced biomass, metabolic activity, and virulence. Monocytes exposed to bacteria from treated biofilms secreted much less IL-1β, while IL-10 was unchanged. Overall, these studies highlight several possible treatments for managing subgingival and periodontal biofilms that merit in vivo testing and validation.Biotics: Probiotics, prebiotics, synbiotics, and postbiotics have been evaluated as adjuncts for oral dysbiosis, but clinical responses remain variable (Ghamari et al., 2026). In a comprehensive review, Di Pierro et al. summarize evidence from in vitro studies, animal models, and clinical trials, with particular focus on Streptococcus salivarius K12 and M18. These strains may support Eubiosis and suppress oral pathogens; however, in vivo efficacy is inconsistent. The authors propose chlorhexidine pre-treatment prior to probiotic administration to reduce competing taxa and facilitate probiotic colonization. The recent review by Anderson et al. (2024) and the experimental studies by Zhang et al. highlight the potential of A. muciniphila as a probiotic or live biotherapeutic product (LBP) for managing oral microbe-linked disorders, including periodontitis. As an alternative to live probiotics against oral pathogens, Zanetta et al. investigated cell-free supernatants (CFS) from Limosilactobacillus reuteri LRE11, Lacticaseibacillus rhamnosus LR04, and Lacticaseibacillus casei LC04 (single strains or mixed culture) on FaDu hypopharyngeal squamous carcinoma cells infected with A. actinomycetemcomitans, F. nucleatum, and P. gingivalis. CFS reduced IL-6 production and infection-associated cytotoxicity; proteomics identified metabolic enzymes, ribosomal/transport proteins, and defense proteins, alongside potentially anti-inflammatory short-chain fatty acids. Vitamin D further enhanced protection, supporting probiotic-derived (viable, heat-killed, or CFS) strategies, with or without vitamin D, for managing oral disease and potentially modulating the tumor microenvironment. Scheithauer et al. assessed Saccharomyces cerevisiae, yeast extracts, and yeast cell wall preparations in oral biofilm models derived from periodontitispositive and healthy donors. Yeast cell wall preparations reduced biofilm density and dysbiosis in vitro, lowered key pathogens (e.g., T. forsythia), and increased health-associated taxa. They also reduced short-chain fatty acid (acetic and butyric acids, among others). Whole yeast and extracts produced qualitatively similar but weaker effects. The mechanism remains unclear but may relate to cell wall components (β-glucans and mannans) that disrupt biofilm structure and/or impede pathogen adhesion, thereby promoting Eubiosis and a healthier metabolic profile. Collectively, these findings support yeast cell wall products as candidate adjuncts for preventing or managing periodontitis and other oral biofilm-associated disorders.In an alternative approach, Li et al. reviewed antimicrobial photodynamic therapy (aPDT), a non-invasive treatment combining a photosensitizer, visible light, and oxygen to generate reactive oxygen species that disrupt biofilms and kill microbial cells. This process is rapid, tissue-sparing, and active against antibiotic-resistant strains. Although it may impact commensals within oral biofilms, optimized photosensitizers and protocols can preferentially target pathogens. Overall, aPDT shows promise as an adjuvant for the management of oral biofilm-associated diseases.Summary: Oral biofilms in health are largely commensal and support epithelial integrity and immune homeostasis. When ecological balance is disrupted, pathogen-enriched biofilms drive oral disease and can contribute to intestinal, systemic, and neuroinflammatory disorders via internal dissemination of pathogenic microbiota, virulence factors, and metabolites. While conventional approaches can reduce harmful oral biofilms, emerging strategies aim to selectively suppress pathobionts while preserving biofilm structure and promoting beneficial commensal microbiota. New strategies that could support this approach are outlined here. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
No takes yet. Share an insight, caveat, or question.
Leanse et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: